

GLOBAL & REGIONAL DAILY

HIGHLIGHTS

January 22, 2021

Global Markets

The ECB kept its monetary policy unchanged y-day, as widely expected, after delivering a stimulus package last month focused on an increase in the PEPP envelope and an extension in the horizon for purchases under the programme. However, market participants focused on the addition of a sentence in the policy statement which said that “If favourable financing conditions can be maintained with asset purchase flows that do not exhaust the envelope over the net purchase horizon of the PEPP, the envelope need not be used in full”. Although the same sentence was mentioned in the minutes of the December ECB meeting, its inclusion in the policy statement was perceived as a hawkish signal. In reaction, sovereign bond yields rose across the continent, while the EUR strengthened, hitting a multi-session peak of 1.2189 against the USD.

Greece

Based on provisional data by the BoG, in Nov-20, travel receipts fell by 80.8%YoY to €61mn. This drop resulted from an 81.1% decline in inbound traveller flows, as average expenditure per trip rose by 12.0%. In Jan-Nov 2020, travel receipts reached €4,247mn, down by 76.3%YoY, due to a 70.6% decline in receipts from residents of EU27 countries and an 81.8% drop in receipts from residents of non-EU27 countries. The average non-resident expenditure per trip in Greece for this period reached €583, up by 2.7%YoY. Meanwhile, in its latest Financial Stability Review, the BoG estimates new NPLs worth at least €8-10bn in 2021 and recommends front-loaded recognition and resolution of NPLs as the only way to restore the robustness of the banking sector and underpin economic recovery.

CESEE

Hungary became the first country in the EU to approve Russia’s Covid-19 vaccine, Sputnik V yesterday while it is also considering to obtain a Chinese vaccine from Sinopharm. On the same footing, Serbia, apart from the Pfizer’s vaccine, has also received one million doses of the Sinopharm vaccine last week, becoming the first candidate European country to start a mass vaccination program with it. Moreover, inoculation with the Sputnik V has already begun in the country. While the EU has pledged to grant candidate countries for accession with EUR70mn for vaccines orders, delays in the roll out of the procedure has forced countries in the region to act independently and get hold of the required amounts of shots on their own.

Contributing Authors

Paraskevi Petropoulou
Senior Economist
ppetropoulou@eurobank.gr

Anna Dimitriadou
Economic Analyst
andimitriadou@eurobank.gr

Maria Kasola
Economic Analyst
mkasola@eurobank.gr

GLOBAL MARKETS
Stock markets




| | Last | ΔD | ΔYTD |
|------------|----------|-------|------|
| S&P 500 | 3853.07 | 0.03% | 2.6% |
| Nikkei 225 | 28631.45 | -0.4% | 4.3% |
| STOXX 600 | 408.28 | -0.6% | 2.3% |

FOREX


| | Last | ΔD | ΔYTD |
|---------|--------|-------|-------|
| EUR/USD | 1.2164 | 0.0% | -0.4% |
| GBP/USD | 1.3669 | -0.5% | 0.0% |
| USD/JPY | 103.63 | -0.1% | -0.4% |

Government Bonds

| (yields) | Last | ΔDbps | ΔYTD bps |
|------------|-------|-------|----------|
| UST - 10yr | 1.09 | -1 | 18 |
| Bund-10yr | -0.50 | -1 | 7 |
| JGB - 10yr | 0.05 | 1 | 3 |


GREECE
Government Bonds

| (yields) | Last | ΔDbps | ΔYTDbps |
|------------------|------|-------|---------|
| 5Y Bond | 0.06 | 1 | -2 |
| 10Y Bond | 0.68 | 3 | 6 |
| Δ(10YBund-10YGG) | 1.18 | 0 | -1 |


ATHENS GENERAL INDEX

EMERGING MARKETS
Stock markets




| | Last | ΔD | ΔYTD |
|-------|---------|-------|---------|
| SOFIX | 499.83 | 0.0% | 11.7% |
| BELEX | 736.37 | -0.7% | -163.5% |
| XU100 | 1540.43 | -0.7% | 431.4% |

FOREX




| | Last | ΔD | ΔYTD |
|---------|--------|-------|------|
| EUR/PLN | 4.538 | -0.1% | 0.5% |
| EUR/RSD | 117.58 | 0.0% | 0.0% |
| USD/TRY | 7.4331 | -0.8% | 0.1% |

Government Bonds

| | Last | ΔDbps | ΔYTD bps |
|--------------|------------------|-------|----------|
| TR 10Y yield | 5.74 | -1 | 33 |
| BG 8Y yield | Invalid Security | | |
| PL 10Y yield | 1.21 | | |


COMMODITIES

| | Last | ΔD | ΔYTD |
|-------------|------|-------|-------|
| GOLD | 1861 | -0.5% | -2.0% |
| BRENT CRUDE | 55 | -1.4% | 6.8% |
| LMEX | 3523 | 0.1% | 3.2% |



Research Team



Dr. Tasos Anastasatos | Group Chief Economist
tanastasatos@eurobank.gr | + 30 214 40 59 706



Anna Dimitriadou
Economic Analyst
andimitriadou@eurobank.gr
+ 30 210 37 18 793



Ioannis Gkionis
Senior Economist
igkionis@eurobank.gr
+ 30 214 40 59 707



Dr. Stylianos Gogos
Economic Analyst
sgogos@eurobank.gr
+ 30 210 37 18 733



Maria Kasola
Economic Analyst
mkasola@eurobank.gr
+ 30 210 33 18 708



Olga Kosma
Research Economist
okosma@eurobank.gr
+ 30 210 37 18 728



Paraskevi Petropoulou
Senior Economist
ppetropoulou@eurobank.gr
+ 30 210 37 18 991



Dr. Theodoros Rapanos
Economic Analyst
v-trapanos@eurobank.gr
+ 30 214 40 59 711



Dr. Theodoros Stamatou
Senior Economist
tstamatou@eurobank.gr
+ 30 214 40 59 708



Elia Tsiampaou
Economic Analyst
etsiampaou@eurobank.gr
+ 30 214 40 59 712

Περισσότερες εκδόσεις μας διαθέσιμες στην ηλεκτρονική διεύθυνση που ακολουθεί: <https://www.eurobank.gr/en/group/economic-research>
Εγγραφείτε ηλεκτρονικά, σε: <https://www.eurobank.gr/el/omilos/oikonomikes-analuseis/forma-ekdilosis-endaferontos>
Ακολουθήστε μας στο **twitter**: https://twitter.com/Eurobank_Group
Ακολουθήστε μας στο **LinkedIn**: <https://www.linkedin.com/company/eurobank>

DISCLAIMER

This report has been issued by Eurobank S.A. ("Eurobank") and may not be reproduced in any manner or provided to any other person. Each person that receives a copy by acceptance thereof represents and agrees that it will not distribute or provide it to any other person. This report is not an offer to buy or sell or a solicitation of an offer to buy or sell the securities mentioned herein. Eurobank and others associated with it may have positions in, and may effect transactions in securities of companies mentioned herein and may also perform or seek to perform investment banking services for those companies. The investments discussed in this report may be unsuitable for investors, depending on the specific investment objectives and financial position. The information contained herein is for informative purposes only and has been obtained from sources believed to be reliable but it has not been verified by Eurobank. The opinions expressed herein may not necessarily coincide with those of any member of Eurobank. No representation or warranty (express or implied) is made as to the accuracy, completeness, correctness, timeliness or fairness of the information or opinions herein, all of which are subject to change without notice. No responsibility or liability whatsoever or howsoever arising is accepted in relation to the contents hereof by Eurobank or any of its directors, officers or employees. Any articles, studies, comments etc. reflect solely the views of their author. Any unsigned notes are deemed to have been produced by the editorial team. Any articles, studies, comments etc. that are signed by members of the editorial team express the personal views of their author.

